Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

No Additional Gain in Quality of Life With Dapagliflozin on Top of TAVI

Todd Neale

May 20, 2025

News Daily News

Procedural Volumes Matter for VT Ablation

Todd Neale

May 12, 2025

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

News Daily News

Lower Risk of Mortality for Shock Patients Transferred to Expert Centers

Caitlin E. Cox

March 17, 2025

Presentation THT 2025

Safety and Feasibility of Renal Venous Afterload Modulation With the Doraya in Acute Decompensated Heart Failure and Persistent Congestion From Insufficient Response to Diuretic Therapy

Presenter: Lucas Zier

February 13, 2025

Presentation THT 2025

Worsening Renal Function Is Common And Associated With Increased Mortality In Cardiogenic Shock: An Analysis From The Multi-Center Cardiogenic Shock Working Group (CSWG) Registry

Presenter: Rachna Kataria

February 12, 2025

Presentation THT 2025

When to Use Devices the Recude Renal Vein Pressure

Presenter: Liviu Klein

February 12, 2025

News Conference News THT 2025

Reprieve System Safely Aids Decongestion in Acute HF: FASTR Pilot RCT

Todd Neale

February 11, 2025

Presentation THT Abstracts 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Renal Dysfunction as a Primary Mechanism of Symptoms in (Most) Patients With HFpEF

Presenter: Jeffrey Testani

February 11, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Michael O'Riordan

January 13, 2025

Advertisement

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

No Additional Gain in Quality of Life With Dapagliflozin on Top of TAVI

Procedural Volumes Matter for VT Ablation

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Lower Risk of Mortality for Shock Patients Transferred to Expert Centers

Safety and Feasibility of Renal Venous Afterload Modulation With the Doraya in Acute Decompensated Heart Failure and Persistent Congestion From Insufficient Response to Diuretic Therapy

Worsening Renal Function Is Common And Associated With Increased Mortality In Cardiogenic Shock: An Analysis From The Multi-Center Cardiogenic Shock Working Group (CSWG) Registry

When to Use Devices the Recude Renal Vein Pressure

Reprieve System Safely Aids Decongestion in Acute HF: FASTR Pilot RCT

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Renal Dysfunction as a Primary Mechanism of Symptoms in (Most) Patients With HFpEF

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content